Sentences with phrase «designing nuclear systems»

Response: Holtec is also an industry leader in designing nuclear systems to withstand cataclysmic natural events such as severe flood, hyper - wind, tornado, tsunami, fire, earthquake, and human mendacity such as a crashing aircraft or missiles, providing absolute and certain safety to the surrounding communities and environment.

Not exact matches

There is intelligence suggesting that Iran has worked on weapon designs, but not that it has developed a delivery system for any potential nuclear warhead.

Decides that, in order to begin to comply with its disarmament obligations, in addition to submitting the required biannual declarations, the Government of Iraq shall provide to UNMOVIC, the IAEA, and the Council, not later than 30 days from the date of this resolution, a currently accurate, full, and complete declaration of all aspects of its programmes to develop chemical, biological, and nuclear weapons, ballistic missiles, and other delivery systems such as unmanned aerial vehicles and dispersal systems designed for use on aircraft, including any holdings and precise locations of such weapons, components, subcomponents, stocks of agents, and related material and equipment, the locations and work of its research, development and production facilities, as well as all other chemical, biological, and nuclear programmes, including any which it claims are for purposes not related to weapon production or material;

He warned that the Chinese could use their role in the programme (designing and constructing nuclear reactors) to build weaknesses into computer systems which allow them to shut down Britain's energy production at will and»... no amount of trade and investment should justify allowing a hostile state easy access to the country's critical national infrastructure.»

He said: «The idea of a like - for - like entirely unchanged replacement of Trident is basically saying we will spend billions and billions and billions of pounds on a nuclear missile system designed with the sole strategic purpose of flattening Moscow at the press of a button.»

No - one who proposes this ever mentions how they plan to maintain flights from or to UK airports without an agreement on Open Skies, or transport nuclear materials without an agreement on Euratom, or get goods into and out of Britain without customs infrastructure in place on the Channel, or allow people to leave and enter the UK without an immigration system designed for them.

The Liberal Democrats today called on the government to scrap the Trident nuclear missile system, in the latest intervention designed to head - off growing dissent from the party's disgruntled left - wingers.

The program was designed to attack and sabotage control systems used in manufacturing facilities, power grids, pipelines, and nuclear plants.

The development and deployment of major technologies potentially crucial to more sustainable energy — such as nuclear power, wind and solar power, biomass conversion and transport infrastructure — are matters of systems design requiring a mix of public and private decision making.

For this reason, nuclear reactors are designed with passive and active safeguards, and separate dedicated systems are used to identify and to neutralise possible faults which could lead to large - scale disasters.

[W] ith the recent advances in computational material design and microtesting, [it] will enable us and our partners to develop materials for safer, cheaper and more sustainable nuclear systems.»

That problem has been addressed by the design of a «new triad» — traditionally the three nuclear limbs comprising intercontinental ballistic missiles, air - delivered gravity bombs, and submarine - launched ballistic missiles — to include other weapons systems.

The spaceships of Project Orion, designed in the late 1950s but never built, had in common their massive size (this one was more than 30 feet in diameter) and a propulsion system that relied on controlled nuclear explosions.

Arnulf Grubler, a researcher at the International Institute for Applied Systems Analysis in Austria, wrote in a 2010 paper published in the journal Energy Policy that France's success in nuclear energy stemmed from establishing a standard design for reactors, centralized decisionmaking and certainty that the government was committed to nuclear power.

However, slow advances in reactor designs, compared to far more rapid advances in renewable energy and energy storage, mean that low - carbon energy systems may end up competing head to head with nuclear.

Researchers from North Carolina State University and the University of Eastern Finland have developed new «sensing skin» technology designed to serve as an early warning system for concrete structures, allowing authorities to respond quickly to damage in everything from nuclear facilities to bridges.

OSU built and operated 1000 MW and 600 MW nuclear steam supply system scale models to help the developer obtain United States Nuclear Regulatory Commission (NRC) Design Certification (DC) for those technonuclear steam supply system scale models to help the developer obtain United States Nuclear Regulatory Commission (NRC) Design Certification (DC) for those technoNuclear Regulatory Commission (NRC) Design Certification (DC) for those technologies.

The agreement brings Ultra Electronics» expertise in reactor protection system design, nucleonic instrumentation, nuclear qualified sensors and associated in - core, specialty cabling to the NuScale design team.

The US nuclear regulator is satisfied that NuScale Power's small modular reactor (SMR) design can operate safely without the need for safety - related electrical systems.

Q24: What is Holtec's experience in designing gravity - driven systems for nuclear plants?

Response: Unlike currently operating nuclear reactors, SMR - 160 has been designed to store the used fuel produced over the entire operating lifetime of the plant in subterranean cavities (formally known as Holtec's HI - STORM UMAX system licensed by the USNRC), occupying a small parcel of land in the plant's backyard.

The «Integral and Separate Effects Test Program for the Investigation and Validation of Passive Safety System Performance of SMRs» project would yield a uniquely configurable set of testing platforms to demonstrate passive safety system performance, accelerate the SMR - 160 and other small modular reactor designs to market, and help license these designs with the U.S. Nuclear Regulatory Commission and international regulSystem Performance of SMRs» project would yield a uniquely configurable set of testing platforms to demonstrate passive safety system performance, accelerate the SMR - 160 and other small modular reactor designs to market, and help license these designs with the U.S. Nuclear Regulatory Commission and international regulsystem performance, accelerate the SMR - 160 and other small modular reactor designs to market, and help license these designs with the U.S. Nuclear Regulatory Commission and international regulators.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transNuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transnuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transNuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transNuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

The science fiction classic WarGames, in which a supercomputer designed to predict outcomes of nuclear war gains access to the real nuclear weapons control system, put it best: «A strange game.

The chemical engineering curriculum and program structure is designed to provide students with thorough knowledge of energy and material balances, thermodynamics, and the physical and reactive characteristics of chemical structures, in order to facilitate creative design and analysis of chemical and nuclear systems.

-- Climate impacts: global temperatures, ice cap melting, ocean currents, ENSO, volcanic impacts, tipping points, severe weather events — Environment impacts: ecosystem changes, disease vectors, coastal flooding, marine ecosystem, agricultural system — Government actions: US political views, world - wide political views, carbon tax / cap - and - trade restrictions, state and city efforts — Reducing GHGs: + electric power systems: fossil fuel use, conservation, solar, wind, geothermal, nuclear, tidal, other + transportation sector: conservation, mass transit, high speed rail, air travel, auto / truck (mileage issues, PHEVs, EVs, biofuels, hydrogen) + architectural structure design: home / office energy use, home / office conservation, passive solar, other

Shouldn't the license to build and operate a nuclear power plant demand that safety systems be designed around a WORST CASE SCENARIO?

The out - of - control status of the 6 Fukushima nuclear reactors and their stored spent fuel rods is a textbook example of «Don't Know Squared — It's What You Don't Know You Don't Know» that can bring down any system designed by humanity.

We need to do a «full court press» to switch from fossil fuels and nuclear (which also releases heat into water on a large scale, and supports nuclear military programs), using existing and near - commercialization battery, solar and wind technology, and design systems to cost - effectively convert the existing 600 - million - plus vehicle fleet rather than waiting for replacement.

Systems are designed to have a probability of less than one in ten thousand for a core meltdown in any given year; but that could mean one every 5 years if nuclear supplied 2 TW of power, or one per year at the 10 TW or higher level (with roughly 10,000 nuclear plants worldwide).

Allison, perhaps the world's leading expert on nuclear security, agrees: «The idea that suicidal terrorists would come in groups of 20 was not the basis on which nuclear power plants and their security systems were designed,» he points out.

Subtitle C: Next Generation Nuclear Plant Project -(Sec. 641) Instructs the Secretary to establish the Next Generation Nuclear Plant Project consisting of design, construction, and operation of a prototype plant, including a nuclear reactor: (1) based on Generation IV Nuclear Energy Systems Initiative research and development; and (2) used to generate electricity or produce hydrogen, or dNuclear Plant Project -(Sec. 641) Instructs the Secretary to establish the Next Generation Nuclear Plant Project consisting of design, construction, and operation of a prototype plant, including a nuclear reactor: (1) based on Generation IV Nuclear Energy Systems Initiative research and development; and (2) used to generate electricity or produce hydrogen, or dNuclear Plant Project consisting of design, construction, and operation of a prototype plant, including a nuclear reactor: (1) based on Generation IV Nuclear Energy Systems Initiative research and development; and (2) used to generate electricity or produce hydrogen, or dnuclear reactor: (1) based on Generation IV Nuclear Energy Systems Initiative research and development; and (2) used to generate electricity or produce hydrogen, or dNuclear Energy Systems Initiative research and development; and (2) used to generate electricity or produce hydrogen, or do both.

In my sometime career as a software designer and programmer in the nuclear industry, I have produced similar types of documentation for software systems that had nuclear safety implications; i.e., the end - to - end validity and quality of the driving design requirements, the internal designs, and the fidelity of the coded software to its design requirements was of critical importance.

``... research on the next generation of nuclear energy systems that can be made available to the market by 2030 or earlier, and that can offer significant advances toward these challenging goals; in particular, six candidate reactor system designs have been identified.

However, all of these designs must demonstrate enhanced safety above and beyond current light water reactor systems if the next generation of nuclear power plants is to grow in number far beyond the current population.

CCS has not yet been commercially deployed at any centralized power plant; the existing nuclear industry, based on reactor designs more than a half - century old and facing renewed public concerns of safety, is in a period of retrenchment, not expansion; and existing solar, wind, biomass, and energy storage systems are not yet mature enough to provide affordable baseload power at terawatt scale.

«Energy production relies on mechanical engineers to design, build and maintain structures and systems that collect, contain and transmit vast amounts of energy, from wind turbine blades, gearboxes and towers to high pressure boilers and nuclear reactors.»

Led various design changes of large scale electrical systems and control systems for Southern Company Nuclear Services, including responsibility for all technical, regulatory, budget and schedule aspects.

SUMMARY OF QUALIFICATIONS * Experience in Externals Design, Piping, Mechanical Design, Product Definition, Unmanned Underwater Vehicles, Military Tanks, Military Aircraft Engines, Power Systems and Nuclear Power.

Tags for this Online Resume: Nuclear Engineer, Criticality Safety, Safety Analysis, Licensing Engineer, System Design

* Used Solidworks and Inventor to design sheet metal electronic enclosures for nuclear safety systems and other applications.